{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T05:35:17Z","timestamp":1776576917900,"version":"3.51.2"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T00:00:00Z","timestamp":1582156800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T00:00:00Z","timestamp":1582156800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"UCSF Integrative Cancer Pilot Award","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}]},{"name":"UCSF Steven & Christine Burd-Safeway Distinguished Professorship","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}]},{"DOI":"10.13039\/100008460","name":"National Center for Complementary and Integrative Health","doi-asserted-by":"publisher","award":["T32AT003997"],"award-info":[{"award-number":["T32AT003997"]}],"id":[{"id":"10.13039\/100008460","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA207749"],"award-info":[{"award-number":["R01CA207749"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R21CA184605"],"award-info":[{"award-number":["R21CA184605"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA181802"],"award-info":[{"award-number":["R01CA181802"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["K07CA197077"],"award-info":[{"award-number":["K07CA197077"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"UCSF Helen Diller Family Chair in Population Science for Urologic Cancer","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Racial and Ethnic Health Disparities"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s40615-020-00724-8","type":"journal-article","created":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T17:02:51Z","timestamp":1582218171000},"page":"996-1002","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["The Problem of Underrepresentation: Black Participants in Lifestyle Trials Among Patients with Prostate Cancer"],"prefix":"10.1007","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3759-3658","authenticated-orcid":false,"given":"Kyle B.","family":"Zuniga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hala","family":"Borno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"June M.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin L.","family":"Van Blarigan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terence W.","family":"Friedlander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunny","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stacey A.","family":"Kenfield","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,2,20]]},"reference":[{"issue":"1","key":"724_CR1","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1097\/00001648-199601000-00014","volume":"7","author":"S Chasan-Taber","year":"1996","unstructured":"Chasan-Taber S, Rimm EB, Stampfer MJ, Spiegelman D, Colditz GA, Giovannucci E, et al. Reproducibility and validity of a self-administered physical activity questionnaire for male health professionals. Epidemiology (Cambridge, Mass). 1996;7(1):81\u20136.","journal-title":"Epidemiology (Cambridge, Mass)"},{"issue":"1","key":"724_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21387","volume":"67","author":"RL Siegel","year":"2017","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7\u201330. https:\/\/doi.org\/10.3322\/caac.21387.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"724_CR3","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.urology.2010.12.046","volume":"78","author":"PM Parker","year":"2011","unstructured":"Parker PM, Rice KR, Sterbis JR, Chen Y, Cullen J, McLeod DG, et al. Prostate cancer in men less than the age of 50: a comparison of race and outcomes. Urology. 2011;78(1):110\u20135. https:\/\/doi.org\/10.1016\/j.urology.2010.12.046.","journal-title":"Urology."},{"issue":"5","key":"724_CR4","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1093\/annonc\/mdx041","volume":"28","author":"BA Mahal","year":"2017","unstructured":"Mahal BA, Chen YW, Muralidhar V, Mahal AR, Choueiri TK, Hoffman KE, et al. Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States. Ann Oncol. 2017;28(5):1098\u2013104. https:\/\/doi.org\/10.1093\/annonc\/mdx041.","journal-title":"Ann Oncol"},{"issue":"5","key":"724_CR5","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1093\/jnci\/93.5.388","volume":"93","author":"RM Hoffman","year":"2001","unstructured":"Hoffman RM, Gilliland FD, Eley JW, Harlan LC, Stephenson RA, Stanford JL, et al. Racial and ethnic differences in advanced-stage prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst. 2001;93(5):388\u201395.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"724_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/pros.22722","volume":"74","author":"JT Bensen","year":"2014","unstructured":"Bensen JT, Xu Z, McKeigue PM, Smith GJ, Fontham ETH, Mohler JL, et al. Admixture mapping of prostate cancer in African Americans participating in the North Carolina-Louisiana prostate cancer project (PCaP). Prostate. 2014;74(1):1\u20139. https:\/\/doi.org\/10.1002\/pros.22722.","journal-title":"Prostate"},{"issue":"2","key":"724_CR7","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.juro.2016.08.104","volume":"197","author":"S Krishna","year":"2017","unstructured":"Krishna S, Fan Y, Jarosek S, Adejoro O, Chamie K, Konety B. Racial disparities in active surveillance for prostate cancer. J Urol. 2017;197(2):342\u20139. https:\/\/doi.org\/10.1016\/j.juro.2016.08.104.","journal-title":"J Urol"},{"issue":"10","key":"724_CR8","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1007\/s10552-018-1065-5","volume":"29","author":"DJ Lee","year":"2018","unstructured":"Lee DJ, Zhao Z, Huang LC, Koyoma T, Resnick MJ, Penson DF, et al. Racial variation in receipt of quality radiation therapy for prostate cancer. Cancer Causes Control. 2018;29(10):895\u20139. https:\/\/doi.org\/10.1007\/s10552-018-1065-5.","journal-title":"Cancer Causes Control"},{"issue":"2","key":"724_CR9","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.clgc.2015.12.003","volume":"14","author":"C Ahaghotu","year":"2016","unstructured":"Ahaghotu C, Tyler R, Sartor O. African American participation in oncology clinical trials--focus on prostate cancer: implications, barriers, and potential solutions. Clin Genitourin Cancer. 2016;14(2):105\u201316. https:\/\/doi.org\/10.1016\/j.clgc.2015.12.003.","journal-title":"Clin Genitourin Cancer"},{"key":"724_CR10","unstructured":"National Institutes of Health; National Cancer Institute; Surveillance, Epidemiology, and End Results Program: Cancer Stat Facts available at https:\/\/seercancergov\/statfacts\/html\/prosthtml Accessed April 1, 2019."},{"issue":"4","key":"724_CR11","doi-asserted-by":"publisher","first-page":"225","DOI":"10.3322\/caac.21234","volume":"64","author":"TA Skolarus","year":"2014","unstructured":"Skolarus TA, Wolf AM, Erb NL, Brooks DD, Rivers BM, Underwood W 3rd, et al. American Cancer Society prostate cancer survivorship care guidelines. CA Cancer J Clin. 2014;64(4):225\u201349. https:\/\/doi.org\/10.3322\/caac.21234.","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"724_CR12","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s00345-016-1914-3","volume":"35","author":"SF Peisch","year":"2017","unstructured":"Peisch SF, Van Blarigan EL, Chan JM, Stampfer MJ, Kenfield SA. Prostate cancer progression and mortality: a review of diet and lifestyle factors. World J Urol. 2017;35(6):867\u201374. https:\/\/doi.org\/10.1007\/s00345-016-1914-3.","journal-title":"World J Urol"},{"issue":"2","key":"724_CR13","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1001\/jama.2010.1972","volume":"305","author":"PS Goode","year":"2011","unstructured":"Goode PS, Burgio KL, Johnson TM 2nd, Clay OJ, Roth DL, Markland AD, et al. Behavioral therapy with or without biofeedback and pelvic floor electrical stimulation for persistent postprostatectomy incontinence: a randomized controlled trial. JAMA. 2011;305(2):151\u20139. https:\/\/doi.org\/10.1001\/jama.2010.1972.","journal-title":"JAMA"},{"issue":"4","key":"724_CR14","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1007\/s00198-015-3399-0","volume":"27","author":"J Uth","year":"2016","unstructured":"Uth J, Hornstrup T, Christensen JF, Christensen KB, Jorgensen NR, Schmidt JF, et al. Efficacy of recreational football on bone health, body composition, and physical functioning in men with prostate cancer undergoing androgen deprivation therapy: 32-week follow-up of the FC prostate randomised controlled trial. Osteoporos Int. 2016;27(4):1507\u201318. https:\/\/doi.org\/10.1007\/s00198-015-3399-0.","journal-title":"Osteoporos Int"},{"issue":"5","key":"724_CR15","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1093\/abm\/kax002","volume":"52","author":"BC Focht","year":"2018","unstructured":"Focht BC, Lucas AR, Grainger E, Simpson C, Fairman CM, Thomas-Ahner JM, et al. Effects of a group-mediated exercise and dietary intervention in the treatment of prostate cancer patients undergoing androgen deprivation therapy: results from the IDEA-P trial. Ann Behav Med. 2018;52(5):412\u201328. https:\/\/doi.org\/10.1093\/abm\/kax002.","journal-title":"Ann Behav Med"},{"issue":"1","key":"724_CR16","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41391-018-0070-9","volume":"22","author":"TM Layne","year":"2019","unstructured":"Layne TM, Graubard BI, Ma X, Mayne ST, Albanes D. Prostate cancer risk factors in black and white men in the NIH-AARP diet and health study. Prostate Cancer Prostatic Dis. 2019;22(1):91\u2013100. https:\/\/doi.org\/10.1038\/s41391-018-0070-9.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"724_CR17","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/pcan.2016.39","volume":"20","author":"EH Allott","year":"2016","unstructured":"Allott EH, Arab L, Su LJ, Farnan L, Fontham ETH, Mohler JL, et al. Saturated fat intake and prostate cancer aggressiveness: results from the population-based North Carolina-Louisiana prostate cancer project. Prostate Cancer Prostatic Dis. 2016;20:48\u201354. https:\/\/doi.org\/10.1038\/pcan.2016.39https:\/\/www.nature.com\/articles\/pcan201639#supplementary-information.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"7","key":"724_CR18","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1002\/jso.23568","volume":"109","author":"S Mohanty","year":"2014","unstructured":"Mohanty S, Bilimoria KY. Comparing national cancer registries: the National Cancer Data Base (NCDB) and the surveillance, epidemiology, and end results (SEER) program. J Surg Oncol. 2014;109(7):629\u201330. https:\/\/doi.org\/10.1002\/jso.23568.","journal-title":"J Surg Oncol"},{"key":"724_CR19","unstructured":"ClinicalTrialsgov: Glossary of Common Site Terms available at https:\/\/clinicaltrialsgov\/ct2\/about-studies\/glossary Accessed March 1, 2019."},{"issue":"2","key":"724_CR20","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/cncr.23157","volume":"112","author":"JG Ford","year":"2008","unstructured":"Ford JG, Howerton MW, Lai GY, Gary TL, Bolen S, Gibbons MC, et al. Barriers to recruiting underrepresented populations to cancer clinical trials: a systematic review. Cancer. 2008;112(2):228\u201342. https:\/\/doi.org\/10.1002\/cncr.23157.","journal-title":"Cancer."},{"issue":"0 7","key":"724_CR21","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1002\/cncr.28575","volume":"120 Suppl 7","author":"MS Chen Jr","year":"2014","unstructured":"Chen MS Jr, Lara PN, Dang JHT, Paterniti DA, Kelly K. Twenty years post-NIH Revitalization Act: enhancing minority participation in clinical trials (EMPaCT): laying the groundwork for improving minority clinical trial accrual: renewing the case for enhancing minority participation in cancer clinical trials. Cancer. 2014;120 Suppl 7(0 7):1091\u20136. https:\/\/doi.org\/10.1002\/cncr.28575.","journal-title":"Cancer"},{"issue":"3","key":"724_CR22","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1089\/jwh.2010.2469","volume":"20","author":"SE Geller","year":"2011","unstructured":"Geller SE, Koch A, Pellettieri B, Carnes M. Inclusion, analysis, and reporting of sex and race\/ethnicity in clinical trials: have we made progress? J Women's Health (2002). 2011;20(3):315\u201320. https:\/\/doi.org\/10.1089\/jwh.2010.2469.","journal-title":"J Women's Health (2002)"},{"issue":"10","key":"724_CR23","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1200\/JCO.2014.58.1751","volume":"33","author":"DE Spratt","year":"2015","unstructured":"Spratt DE, Osborne JR. Disparities in castration-resistant prostate cancer trials. J Clin Oncol. 2015;33(10):1101\u20133. https:\/\/doi.org\/10.1200\/JCO.2014.58.1751.","journal-title":"J Clin Oncol"},{"issue":"2","key":"724_CR24","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.juro.2018.09.029","volume":"201","author":"AS Balakrishnan","year":"2019","unstructured":"Balakrishnan AS, Palmer NR, Fergus KB, Gaither TW, Baradaran N, Ndoye M, et al. Minority recruitment trends in phase III prostate cancer clinical trials (2003 to 2014): progress and critical areas for improvement. J Urol. 2019;201(2):259\u201367. https:\/\/doi.org\/10.1016\/j.juro.2018.09.029.","journal-title":"J Urol"},{"issue":"6","key":"724_CR25","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1200\/JCO.2009.26.2469","volume":"28","author":"KA Moses","year":"2010","unstructured":"Moses KA, Paciorek AT, Penson DF, Carroll PR, Master VA. Impact of ethnicity on primary treatment choice and mortality in men with prostate cancer: data from CaPSURE. J Clin Oncol. 2010;28(6):1069\u201374. https:\/\/doi.org\/10.1200\/JCO.2009.26.2469.","journal-title":"J Clin Oncol"},{"issue":"7","key":"724_CR26","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1001\/jamaoncol.2019.0826","volume":"5","author":"RT Dess","year":"2019","unstructured":"Dess RT, Hartman HE, Mahal BA, Soni PD, Jackson WC, Cooperberg MR, et al. Association of black race with prostate cancer\u2013specific and other-cause mortality. JAMA Oncol. 2019;5(7):975\u201383. https:\/\/doi.org\/10.1001\/jamaoncol.2019.0826.","journal-title":"JAMA Oncol"},{"issue":"5","key":"724_CR27","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1007\/s00520-013-2092-0","volume":"22","author":"KM Winters-Stone","year":"2014","unstructured":"Winters-Stone KM, Lyons KS, Bennett JA, Beer TM. Patterns and predictors of symptom incongruence in older couples coping with prostate cancer. Support Care Cancer. 2014;22(5):1341\u20138. https:\/\/doi.org\/10.1007\/s00520-013-2092-0.","journal-title":"Support Care Cancer"},{"issue":"1","key":"724_CR28","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.apmr.2014.08.010","volume":"96","author":"KM Winters-Stone","year":"2015","unstructured":"Winters-Stone KM, Dobek JC, Bennett JA, Dieckmann NF, Maddalozzo GF, Ryan CW, et al. Resistance training reduces disability in prostate cancer survivors on androgen deprivation therapy: evidence from a randomized controlled trial. Arch Phys Med Rehabil. 2015;96(1):7\u201314. https:\/\/doi.org\/10.1016\/j.apmr.2014.08.010.","journal-title":"Arch Phys Med Rehabil"},{"issue":"4","key":"724_CR29","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s11764-015-0509-0","volume":"10","author":"KM Winters-Stone","year":"2016","unstructured":"Winters-Stone KM, Lyons KS, Dobek J, Dieckmann NF, Bennett JA, Nail L, et al. Benefits of partnered strength training for prostate cancer survivors and spouses: results from a randomized controlled trial of the exercising together project. J Cancer Surviv. 2016;10(4):633\u201344. https:\/\/doi.org\/10.1007\/s11764-015-0509-0.","journal-title":"J Cancer Surviv"},{"issue":"2","key":"724_CR30","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1093\/jnci\/dji009","volume":"97","author":"SM Lippman","year":"2005","unstructured":"Lippman SM, Goodman PJ, Klein EA, Parnes HL, Thompson IM, Kristal AR, et al. Designing the selenium and vitamin E cancer prevention trial (SELECT). JNCI. 2005;97(2):94\u2013102. https:\/\/doi.org\/10.1093\/jnci\/dji009.","journal-title":"JNCI"},{"issue":"4","key":"724_CR31","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1177\/1740774510373491","volume":"7","author":"SP Heiney","year":"2010","unstructured":"Heiney SP, Arp Adams S, Drake BF, Bryant LH, Bridges L, Hebert JR. Successful subject recruitment for a prostate cancer behavioral intervention trial. Clin Trials (London, England). 2010;7(4):411\u20137. https:\/\/doi.org\/10.1177\/1740774510373491.","journal-title":"Clin Trials (London, England)"}],"container-title":["Journal of Racial and Ethnic Health Disparities"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40615-020-00724-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40615-020-00724-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40615-020-00724-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T19:34:52Z","timestamp":1613763292000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40615-020-00724-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,20]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["724"],"URL":"https:\/\/doi.org\/10.1007\/s40615-020-00724-8","relation":{},"ISSN":["2197-3792","2196-8837"],"issn-type":[{"value":"2197-3792","type":"print"},{"value":"2196-8837","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,20]]},"assertion":[{"value":"9 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Kyle B Zuniga has no conflicts of interest to disclose. Hala Borno has a family member with employment, leadership, and stock and other ownership interests in Collective Health. June M Chan has a family member with employment; travel, accommodation, and expense payments; stock and other ownership interests; and research funding from GRAIL; a family member with employment; travel, accommodation, and expense payments; and research funding from Myriad Genetics; institutional affiliation that has research funding from Genomic Health; and research funding from GenomeDx. Erin L Van Blarigan has no conflicts of interest to disclose. Terrence Friedlander has a consulting\/advisory role in Genentech; a consulting\/advisory role in AstraZeneca; a consulting\/advisory role and travel, accommodations, and expense payments in Clovis Oncology; a consulting\/advisory role in Foundation Medicine; a leadership role in Med BioGene; a speakers\u2019 bureau role in Sanofi; a speakers\u2019 bureau role in Dendreon; a speakers\u2019 bureau role in Astellas Medivation; travel, accommodations, and expenses payments in AstraZeneca\/MedImmune; travel, accommodations, and expenses payments in Genentech\/Roche; honoraria in EMD Soreno; research funding from Janssen; research funding from ImClone Systems; research funding from Aragon Pharmaceuticals; and research funding from GlaxoSmithKline. Sunny Wang has institutional affiliation that has research funding from Clovis Oncology. Li Zhang has no conflicts of interest to disclose. Stacey A Kenfield has research funding from GenomeDx and has a consulting\/advisory role at Mojo Enterprises, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee of the University of California, San Francisco and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Informed consent was deemed unnecessary as de-identified data was gathered retrospectively from publicly available sources or in aggregate from corresponding authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"The datasets generated during and analyzed during the current study for the reference population are publicly available in the Surveillance, Epidemiology, and End Results (SEER) repository, . The datasets generated and analyzed during the current study for the study population were obtained from trial publications, , and corresponding author request, and aggregate data can be found in Online Resource 2.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}}]}}